Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study por Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Obter o texto integral

Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan por Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Obter o texto integral

Successful treatment of psoriasis vulgaris with ixekizumab in a patient with concurrent Sjögren’s syndrome presenting with dry eye and incomplete SLE por Marina Onda, Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Obter o texto integral

Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan por Teppei Hagino, Mai Yoshida, Risa Hamada, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Obter o texto integral

Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study por Teppei Hagino, Risa Hamada, Mai Yoshida, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Obter o texto integral

Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis por Teppei Hagino, Mai Yoshida, Risa Hamada, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Obter o texto integral

Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks por Teppei Hagino, Risa Hamada, Mai Yoshida, Eita Fujimoto, Hidehisa Saeki, Naoko Kanda

Obter o texto integral

Early itch relief with upadacitinib predicts later skin clearance in Atopic dermatitis por Teppei Hagino, Mai Yoshida, Risa Hamada, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Obter o texto integral